



# Corporate Presentation

## November 2024

NASDAQ: TNXP

Version P06020 November 4, 2024 (Doc 1532)

© 2024 Tonix Pharmaceuticals Holding Corp.



# Cautionary Note on Forward-Looking Statements

Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The forward-looking statements in this presentation are made as of the date of this presentation, even if subsequently made available by Tonix on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward-looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports and current reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

# Who We Are

Tonix is committed to developing and marketing therapeutics to treat pain, neurologic, psychiatric and addiction conditions through our ***central nervous system portfolio*** and within other areas of ***high unmet need***, including immunology, infectious disease, and rare disease






*...Transforming therapies for pain management and vaccines for public health challenges...*



**TONIX**  
PHARMACEUTICALS

**CNS:  
KEY DEVELOPMENT  
CANDIDATES**

# Key Clinical Programs

Molecule*	Indication	Phase 1	Phase 2	Phase 3	NDA Submission
<b>TNX-102 SL</b> Cyclobenzaprine HCl Sublingual Tablets	<b>Fibromyalgia</b> <i>Granted FDA Fast Track Designation</i>	 Submitted NDA to FDA in October 2024			
	<b>Acute Stress Disorder</b>	 Phase 2 Study** Start Expected 4Q'24			
<b>TNX-1300</b> Cocaine Esterase <i>NIDA Funded</i>	<b>Cocaine Intoxication</b> <i>Granted FDA Breakthrough Therapy Designation</i>	 Phase 2 Study Ongoing			
<b>TNX-2900</b> Intranasal Potentiated Oxytocin	<b>Prader-Willi Syndrome</b> <i>FDA Orphan Drug and Rare Pediatric Disease Designations</i>	 Phase 2 Ready			
<b>TNX-1500</b> Anti-CD40L mAb	<b>Organ Transplant Rejection/ Autoimmune Conditions</b>	 Phase 1 Study Ongoing <span style="margin-left: 20px;"><i>Clinical Stage Completed</i></span>			

\*All of Tonix's product candidates are investigational new drugs or biologics; their safety and efficacy have not been established and none has been approved for any indication.

\*\*Investigator-initiated study

# CNS-Focused Fully-Integrated Biopharma with Preclinical, Clinical and Commercial Stage Products



## **TNX-102 SL for Fibromyalgia: Submitted New Drug Application (NDA) to FDA in October 2024**

- FDA decision on NDA acceptance for review expected December 2024
- Granted FDA Fast Track Designation
- Two Phase 3 trials completed with statistical significance on primary endpoint
- FDA decision on NDA approval expected 2025; potential product launch in 2025



## **Marketed Products**

- Zembrace® and Tosymra® indicated for the treatment of acute migraine



## **Pipeline**

- Phase 2 biologic cocaine antidote, FDA “Breakthrough Therapy Designation”
- Phase 1 anti-CD40L monoclonal antibody to prevent organ transplant rejection



## **Strategic Partnerships**

- With government institutions, world-class academic & research organizations



## **Internal Capabilities**

- Commercial prescription drug sales
- R&D and potential for clinical-trial scale manufacturing

# TNX-102 SL\*

(Cyclobenzaprine HCl Sublingual Tablets)

---

*A unique, sublingual formulation of cyclobenzaprine designed to optimize delivery and absorption*

\*5.6 mg once-daily at bedtime



# Fibromyalgia is a Large, Underserved and Dissatisfied Population

- **More than 10 million U.S. adults are affected – predominantly women<sup>1,2</sup>**
  - Debilitating and life altering condition
  - Significant economic impact
- **Patients have expressed dissatisfaction, despite three FDA approved drugs<sup>3,4</sup>**
  - 85% of patients fail first-line therapy<sup>5</sup>: efficacy variability, tolerability issues especially when used long-term and lack of broad-spectrum activity
  - Typical for patients to rotate between drugs and be on multiple drugs at the same time; 79% of FM patients are on multiple therapies<sup>5</sup>
- **~2.7 million FM patients diagnosed and treated<sup>6</sup>**
  - >22 million prescriptions are issued for the treatment of fibromyalgia (on- and off-label usage) each year<sup>7,8</sup>
- **No new Rx product since 2009**
- *The treatment objective is to restore functionality and quality of life while avoiding significant side effects*

<sup>1</sup>American College of Rheumatology ([www.ACRPatientInfo.org](http://www.ACRPatientInfo.org) accessed May 7, 2019) – prevalence rate of 2-4% for U.S. adult population (~250 million)

<sup>2</sup>Vincent A, et al. *Arthritis Care Res (Hoboken)*. 2013 65(5):786-92. doi: 10.1002; diagnosed prevalence rate was 1.1% of adult population or 50% of the prevalent population

<sup>3</sup>Robinson RL, et al. *Pain Med*. 2012 13(10):1366-76. doi: 10.1111; 85% received drug treatment

<sup>4</sup>The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella)

<sup>5</sup>EVERSANA primary physician research, May 2024; commissioned by Tonix

<sup>6</sup>EVERSANA analysis of claims database, May 2024; commissioned by Tonix

<sup>7</sup>Product sales derived from IMS MIDAS; IMS NDTI used to factor usage for fibromyalgia; data accessed April 2015.

<sup>8</sup>Market research by Frost & Sullivan, commissioned by Tonix, 2011





# About Fibromyalgia

Fibromyalgia is a **chronic pain disorder** resulting from amplified sensory and pain signaling within the CNS – now recognized as ***nociceptive pain***<sup>1-4</sup>

Fibromyalgia is a **syndrome** comprised of the ***symptoms***: chronic widespread pain, ***nonrestorative sleep***, and ***fatigue***



**Fibromyalgia is considered a chronic overlapping pain condition (COPC)<sup>5</sup>  
- the *only COPC with any FDA-approved drugs*<sup>6</sup>**

**Fibromyalgia is the prototypic nociceptive syndrome**

<sup>1</sup>Trouvin AP, et al. *Best Pract Res Clin Rheumatol*. 2019;33(3):101415.

<sup>2</sup>Fitzcharles MA, et al. *Lancet* 2021;397:2098-110

<sup>3</sup>Kaplan CM, et al. *Nat Rev Neurol*. 2024 20(6):347-363..

<sup>4</sup>Clauw DJ. *Ann Rheum Dis*. 2024 ard-2023-225327. doi: 10.1136/ard-2023-225327.

<sup>5</sup>Maixner W, et al. *J Pain*. 2016;17(9 Suppl):T93-T107.


<sup>6</sup>The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica®); Duloxetine (Cymbalta®); Milnacipran (Savella®)



# The Third Primary Type of Pain: Nociplastic Pain<sup>1-5</sup>

**Nociplastic syndrome includes:**

- (1) widespread pain
- (2) fatigue
- (3) sleep disturbances
- (4) cognitive dysfunction (“brain fog”)



<sup>1</sup>Trouvin AP, et al. *Best Pract Res Clin Rheumatol.* 2019;33(3):101415.

<sup>2</sup>Fitzcharles MA, et al. *Lancet* 2021;397:2098-110

<sup>3</sup>Kaplan CM, et al. *Nat Rev Neurol.* 2024 20(6):347-363..

<sup>4</sup>Clauw DJ. *Ann Rheum Dis.* 2024 ard-2023-225327. doi: 10.1136/ard-2023-225327.

<sup>5</sup>Kureshi S et al. *Healthcare (Basel)* 2024 12(3): 289.

\*ME/CFS = chronic fatigue syndrome / myalgic encephalomyelitis


\*\*PCS = post concussive syndrome.

\*\*\*IBD – irritable bowel syndrome



# Poor Sleep and Pain have Bi-directional Reinforcing Effects<sup>1</sup>

- **Poor sleep and pain form a vicious cycle in driving fibromyalgia decompensation**
  - Can't sleep → worse pain / In pain → can't sleep
  - Poor sleep and pain contribute to persistence, chronicity and severity
  - Syndrome includes symptoms of fatigue and brain fog
- **Treating sleep disturbance in fibromyalgia has the potential to break the vicious cycle**
  - Potential to remove an obstacle to recovery
  - Using the right medicine is important – some sedative/hypnotics don't work<sup>1,2</sup>



<sup>1</sup>Moldofsky H, et al. *J Rheumatol*. 1996;23:529–533.  
<sup>2</sup>Grönwald M, et al. *Clin Rheumatol*. 1993;12(2):186–191




## TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets)

- **Non-opioid analgesic designed for long-term daily bedtime use in fibromyalgia patients**
  - Targets non-restorative sleep
  - Potent binding and antagonist activities at four post-synaptic receptors
    - serotonin-5-HT<sub>2A</sub>
    - $\alpha$ 1-adrenergic
    - histaminergic-H<sub>1</sub>
    - muscarinic-M<sub>1</sub>
  - No recognized risk for abuse
- **Improves sleep quality, does not increase sleep quantity:**
  - Not a traditional hypnotic or sedative
- **Proprietary, sublingual transmucosal formulation of cyclobenzaprine designed to optimize delivery and absorption**




# TNX-102 SL: Sublingual Administration and Transmucosal Delivery

- Advantages of the sublingual route
- Faster absorption provides PK that is ideal for bedtime dosing
- Bypasses “first-pass” hepatic metabolism
- Reduced metabolism of parent CBP to active metabolite norcyclobenzaprine (nCBP)



# TNX-102 SL for FM: Non-opioid, Centrally-Acting Analgesic that Offers a Potentially Transformative Approach by Facilitating Restorative Sleep <sup>1</sup>

Potent binding and antagonist activities at four key receptors facilitate *restorative sleep*



- *serotonergic-5-HT2A*
- *adrenergic- $\alpha$ 1*
- *histaminergic-H1*
- *muscarinic-M1*

## ***Key Differentiators***

### Relative to Oral Cyclobenzaprine

- Lower daytime exposure
- Avoids first-pass metabolism
- Reduces risk of pharmacological interference from major metabolite

### Relative to Standard of Care

- Potential for better tolerability while maintaining efficacy
- Not scheduled nor with recognized abuse potential

Issued patents expected to provide exclusivity to 2034

<sup>1</sup>TNX-102 SL has not been approved for any indication.

<sup>1</sup>TNX-102 SL is an investigational new drug, its safety and efficacy has not been established and it has not been approved for any indication.

# Fibromyalgia is Believed to Result from Chronic Pain or Prior Stress Experiences

## The pain system evolved to detect acute pain

- The body's "check engine" light

## Chronic pain breaks down the system that determines whether a sensory experience is painful

- Chronic pain results in nociplastic syndromes
- Nociplastic syndrome was formerly known as "Central and Peripheral Sensitization"

## Chronic Overlapping Pain Conditions (COPCs) are Nociplastic Syndromes:

- Fibromyalgia
- ME/CFS
- Migraine
- Irritable Bowel Syndrome
- Endometriosis
- Low Back Pain

## Stresses that may precede or precipitate FM include:

### Chronic nociceptive pain

- e.g., osteoarthritis

### Chronic neuropathic pain

- e.g., diabetic neuropathy

### Infectious

- e.g., viral illness

### Cancer

- e.g., breast cancer

### Chemical

- e.g., cancer chemotherapy

### Traumatic

- e.g., motor vehicle accident

### Head trauma

- e.g., post-concussive syndrome

### Physiologic

- e.g., disturbed sleep





# Common Chronic Conditions are a Challenge for Pharma

## Fibromyalgia is a common chronic disease<sup>1</sup>

- Chronic pain syndrome that persists for years or decades

## No animal model is recognized for nociplastic syndromes or its component symptoms

- Widespread pain
- Fatigue
- Sleep disturbance
- Cognitive impairment

## Nociplastic symptoms are subjective

- Humans need to report symptoms using scales

## Clinical trials measuring subjective symptoms are challenging

- Placebo response is typically observed
- Long-term therapy means requires long-term tolerability

<sup>1</sup>The U.S. Centers for Disease Control defines chronic diseases as “conditions that last 1 year or more and require ongoing medical attention or limit activities of daily living or both.” [www.cdc.gov/chronicdisease/about/index.htm](http://www.cdc.gov/chronicdisease/about/index.htm). (accessed Jan 28, 2024)





## Common Chronic Conditions are a Challenge for Society

**The Opioid Crisis in the U.S. was driven by mistreatment of chronic pain, which was often nociplastic pain**

- The epidemic of prescription pain killers was addressed by regulations which limited the availability of opioids
- Many individuals who are opioid dependent have transitioned to illegal street heroin and fentanyl
- Illegal drugs contribute to homelessness

**There is an unmet need for non-opioid analgesics that address nociplastic pain**

- No new drug for fibromyalgia has been approved since 2009



# Current FDA-Approved Fibromyalgia Drugs were Repurposed<sup>1</sup>

Human investigation was required to find drugs that improve pain in fibromyalgia

- No current product addresses pain, poor sleep and fatigue

Drug		Lyrica® (pregabalin) - Pfizer	Cymbalta® (duloxetine) - Lilly Savella® (milnacipran) - AbbVie
Initial Indication Sought		Epilepsy	Depression
Class		Gabapentinoid	SNRI
Mechanism		Slow neuron firing	Block NE reuptake
Fibromyalgia Activity	Pain	+	+
	Sleep	+	-
	Fatigue	-	+
Tolerability Issues	Sleep	-	+
	Fatigue	+	-
		Weight gain	Blood Pressure increases
			Sexual function impairment
			GI issues

<sup>1</sup>The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella)



# Fibromyalgia Program Status

## TNX-102 SL

Cyclobenzaprine Sublingual  
Tablets

Fibromyalgia

**NDA Submitted to FDA in October 2024**

- First pivotal Phase 3 study (*RELIEF*) reported – December 2020<sup>1</sup>
- Second Phase 3 study (*RALLY*) missed primary endpoint – July 2021
- Confirmatory pivotal Phase 3 study (*RESILIENT*) reported – December 2023
- Granted FDA Fast Track Designation
- Submitted NDA to FDA in October 2024

### Next Steps:

- **NDA acceptance for review expected December 2024**
- **FDA decision on NDA approval expected 2025**

<sup>1</sup>Lederman S, et al. *Arthritis Care Res (Hoboken)*. 2023 Nov;75(11):2359-2368. doi: 10.1002. © 2024 Tonix Pharmaceuticals Holding Corp.

# TNX-102 SL: Phase 3 *RESILIENT* Study Design



## General study characteristics:

- Randomized, double-blind, multicenter, placebo-controlled study in fibromyalgia
- 33 U.S. sites enrolled 457 participants with fibromyalgia as defined by 2016 Revisions to the 2010/2011 FM Diagnostic Criteria<sup>1</sup>

## Primary Endpoint:

- Change from baseline to Week 14 (TNX-102 SL vs. placebo) in weekly averages of daily diary average pain severity score

**TNX-102 SL once-daily at bedtime**  
5.6 mg (2 x 2.8 mg tablets)\*

**Placebo once-daily at bedtime**

14 weeks

\*Two-week run-in at 2.8 mg dose at bedtime followed by 12 weeks at 5.6 mg dose

ClinicalTrials.gov Identifier: **NCT05273749**

Study Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT)

Trial ID: TNY-CY-F307 ('RESILIENT')


<sup>1</sup>Wolfe F, et al. *Semin Arthritis Rheum.* 2016 46(3):319-329. doi: 10.1016

# RESILIENT Primary Outcome Measure

## Reduction in Widespread Pain



### Weekly Average of Daily Diary NRS Ratings of Average Pain Over Prior 24 Hours



\*p<0.01; \*\*p<0.001; \*\*\*p<0.0001

Week 14 LS mean (SE) change from baseline for TNX-102 SL -1.82 (0.12) and for placebo -1.16 (0.12); LSMD from placebo -0.65 (0.16); **p=0.00005#**

#Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction. Abbreviations: LS, least squares; LSMD, least squares mean difference; NRS, numerical rating scale; SE, standard error



# Summary of Key Pre-Specified Secondary Outcome Measures

<u>Rating Scale</u>	<u>Week 14</u>	<u>Met**</u>
Patient Global Impression of Change (PGIC)	<i>p &lt; 0.001</i>	✓
Fibromyalgia Impact Questionnaire - Symptoms	<i>p &lt; 0.001</i>	✓
Fibromyalgia Impact Questionnaire - Function	<i>p = 0.001</i>	✓
PROMIS Sleep Disturbance	<i>p &lt; 0.001</i>	✓
PROMIS Fatigue	<i>p &lt; 0.001</i>	✓
Weekly average of daily Sleep Quality scores	<i>p &lt; 0.001</i>	✓

\*In order of statistical serial gate-keeping hierarchy (or, “waterfall”) to control overall Type 1 error

\*\*Statistical significance met



# RESILIENT Pre-Specified Primary Endpoint

## Summary<sup>1</sup>

- TNX-102 SL demonstrated statistically significant improvement in mean weekly pain scores over placebo at Week 14
- [P-value of 0.00005](#) is *highly* statistically significant

## Additional Findings

- Effect size 0.38
- All pre-specified sensitivity analyses of the primary endpoint show statistical significance ( $p \leq 0.001$ )
- Rapid onset of action:  $p$ -values  $<0.01$  at each weekly time point, including Week 1

<sup>1</sup>EULAR 2024. "Targeting Non-Restorative Sleep in Fibromyalgia with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) Significantly Improves Pain in RESILIENT, a Confirmatory Phase 3 Randomized Clinical Trial." <https://www.tonixpharma.com/wp-content/uploads/2024/06/EULAR-2024-FM-Poster-vFinal.pdf>



# RESILIENT Safety Summary

Among participants randomized to TNX-102 SL and to placebo, 81.0% and 79.6%, respectively, completed the study  
TNX-102 SL was generally well tolerated with an adverse event (AE) profile comparable to prior fibromyalgia studies

- No new safety signals were observed
- AE-related study discontinuations occurred in 6.1% and 3.6% of patients in the TNX-102 SL and placebo groups, respectively
- Events rated as mild or moderate made up 97.2% of AEs on placebo and 99.1% on TNX-102 SL
- As observed in prior studies with TNX-102 SL, oral administration site AEs were higher in TNX-102 SL than placebo, 42.9% and 10.2%, respectively
  - Most common oral AEs were oral hypoaesthesia, product taste abnormal, oral paraesthesia, and tongue discomfort (see table on next slide)
  - Nearly all of these common oral AEs were temporally related to dosing and lasted <60 minutes
- Serious Adverse Events (SAEs)
  - Three placebo participants experienced an SAE:
    - 1. Pneumonia, 2. Muscular weakness, and 3. Hypertension/Angina/Coronary Artery Disease
  - Two TNX-102 SL participants experienced an SAE
    - 1. Renal carcinoma deemed not related to study drug
    - 2. Acute pancreatitis with onset 14 days after completion of treatment phase, deemed ‘possibly related’\* to study drug
      - Outcome: ‘Recovered/Resolved’
      - \*Note: participant was non-compliant with end of treatment study visits, and the last dose before onset of SAE was not known at the time that relationship with study drug was assessed by Investigator and Sponsor



## Treatment-Emergent Adverse Events (TEAEs) at Rate of $\geq 3\%$ in Either Treatment Group

System Organ Class Preferred Term	TNX-102 SL N=231	Placebo N=226	Total* N=457
<b>Systemic Adverse Events</b>			
COVID-19	10 (4.3%)	7 (3.1%)	17 (3.7%)
Somnolence	7 (3.0%)	3 (1.3%)	10 (2.2%)
Headache	7 (3.0%)	4 (1.8%)	11 (2.4%)
<b>Oral Cavity Adverse Events</b>			
Hypoaesthesia oral	55 (23.8%)	1 (0.4%)	56 (12.3%)
Product taste abnormal	27 (11.7%)	2 (0.9%)	29 (6.3%)
Paraesthesia oral	16 (6.9%)	2 (0.9%)	18 (3.9%)
Tongue discomfort	16 (6.9%)	0 (0.0%)	16 (3.5%)

\*Safety Population

### Changes in Sexual Functioning Questionnaire short form (CSFQ-14) was a safety measure in the study

- In females, CSFQ-14 total score improved (indicating better sexual functioning) to a greater extent in the TNX-102 SL group compared with placebo,  $p=0.010$
- Orgasm/Completion and Desire/Frequency were improved
- Potential tolerability advantage over pharmacotherapeutics with potent serotonin reuptake inhibition



# TNX-102 SL Showed Activity on Pain, Sleep and Fatigue and was Generally Well Tolerated in the RESILIENT Study<sup>1</sup>

<b>Drug</b>		TNX-102 SL
<b>Initial Indication of active ingredient</b>		Muscle spasm <sup>1</sup>
<b>Class</b>		Tricyclic
<b>Mechanism</b>		Antagonist at 4 post-synaptic receptors <sup>2</sup>
<b>Fibromyalgia Activity</b>	<b>Pain</b>	+
	<b>Sleep</b>	+
	<b>Fatigue</b>	+
<b>Tolerability Issues</b>	Sleep	-
	Fatigue	-
	Oral administration site reaction <sup>3</sup>	+

<sup>1</sup>Flexeril® and Amrix® are oral formulations of cyclobenzaprine indicated for short term (2-3 weeks) treatment of muscle spasm

<sup>2</sup>Four receptors are: serotonergic-5-HT<sub>2A</sub>, adrenergic-α<sub>1</sub>, histaminergic-H<sub>1</sub>, and muscarinic-M<sub>1</sub> cholinergic receptors

<sup>3</sup>TNX-102 SL was generally well tolerated with an adverse event profile comparable to prior studies and no new safety signals were observed. In both pivotal studies, the most common treatment-emergent adverse event was tongue or mouth numbness at the administration site, which was temporally related to dosing, self-limited, never rated as severe, and rarely led to study discontinuation (one participant in each study).



# ~50% of U.S. Fibromyalgia Patients are on Medicare: Prescription Coverage in Medicare Stands to Benefit from Changes in IRA


## Approximately 50% of fibromyalgia patients are on Medicare

- EVERSANA analysis of claims database consisting of 2.2M patients, for which 1.2M claims were submitted throughout March 2002-March 2023<sup>1</sup>

## Beneficial Changes in 2025 to Medicare Part D through Inflation Reduction Act (IRA)<sup>2</sup>

- Medicare prescription payment plan to offer enrollees the option to pay out-of-pocket prescription drug costs in the form of capped monthly installment payments instead of all at once at the pharmacy
- Annual out-of-pocket costs will be capped at \$2,000 in year 2025
- Will replace the existing Coverage Gap Discount Program, which sunsets as of January 1, 2025

## Fibromyalgia Patients by Coverage<sup>1</sup>




<sup>1</sup> EVERSANA analysis of claims database, May 2024; commissioned by Tonix

<sup>2</sup> Source: [Final CY 2025 Part D Redesign Program Instructions Fact Sheet | CMS](#)


# Prescribers Interviewed Expressed Broad Dissatisfaction with Available Fibromyalgia Medications: Results of Primary Research<sup>1</sup>



Perspectives on FM Therapies from Prescribers Interviewed		
Drug	Positives	Negatives
<b>Duloxetine</b> (Cymbalta, generic)	<ul style="list-style-type: none"> <li>Relatively high efficacy (compared to alternatives)</li> <li>Can be titrated slowly from 20mg to 120mg</li> </ul>	<ul style="list-style-type: none"> <li>Tolerability issues: worsening depression, insomnia</li> <li>Seldom used as a monotherapy; often requires adjunct</li> </ul>
<b>Pregabalin</b> (Lyrica, generic)	<ul style="list-style-type: none"> <li>Relatively high efficacy (compared to alternatives)</li> <li>Can often be safely combined with other medications</li> </ul>	<ul style="list-style-type: none"> <li>Suboptimal for long-term use (e.g., weight gain)</li> <li>Schedule V status makes some HCPs more cautious to Rx</li> </ul>
<b>Savella</b> (milnacipran)	<ul style="list-style-type: none"> <li>Offers another option if patient fails Cymbalta or Lyrica</li> </ul>	<ul style="list-style-type: none"> <li>Subpar efficacy does not counterbalance tolerability issues</li> <li>High cost and access constraints (~\$50/month)</li> </ul>
<b>Cyclobenzaprine</b> (Flexeril, generic; oral formulation, off-label)	<ul style="list-style-type: none"> <li>Active for initiating and sustaining sleep; can be titrated up</li> <li>Active for pain driven by stiffness and muscle spasms</li> </ul>	<ul style="list-style-type: none"> <li>Mixed perspectives on pain benefit independent of sleep</li> <li>Suboptimal long-term results as efficacy wanes</li> </ul>



**85% of patients (avg) fail first line therapy**



**79% of FM patients (avg) are on multiple therapies**

<sup>1</sup>EVERSANA primary physician research, May 2024; commissioned by Tonix

# Opportunity for a New, Unique Fibromyalgia Treatment Option: Results of Primary Research from EVERSANA<sup>1,2</sup>



## FM Landscape

- Prescribers indicate a **very high unmet need** in FM (ranked  $\geq 4.0$  on a 5-point scale)
- Prescribers report there is **no standard of care in FM**, employ an **individualized approach** based on symptomology
- No new treatments approved since 2009
- Prescribers report minimal promotional activities by any pharmaceutical company
- Highly concentrated prescriber base with 50% of patients treated by ~16k physicians



## Physician Primary Market Research

- **Physicians reacted positively to the efficacy and safety profile of TNX-102 SL (based on Phase 3 Study results)**
- Median interest = 4.0 on a 5-point scale
- Driving attributes included **strong efficacy, safety and tolerability**
- Unique & differentiating efficacy features included improvements in **sleep and fatigue**



## Anticipated Use

- **Physicians indicated intended use in 40% of their FM patients**
- Majority of respondents indicated TNX-102 SL would be their first choice, if accessible
- Physicians surveyed indicated they are well-equipped to deal with access restrictions including prior authorizations and step-edits


<sup>1</sup> EVERSANA primary physician research, May 2024; commissioned by Tonix

<sup>2</sup> EVERSANA analysis of claims database, May 2024; commissioned by Tonix

# Many Fibromyalgia Patients are Prescribed Off-Label Drugs; ~53% FM Patients Prescribed Opioids Off-Label<sup>1,2</sup>



% FM Patients (after index<sup>3</sup> date)



<sup>1</sup> 2022-2023

<sup>2</sup> EVERSANA analysis of claims database, May 2024; commissioned by Tonix

<sup>3</sup> Index date refers to date when ICD10 code was entered into database



# Planning for TNX-102 SL Launch and Marketing

Several companies that successfully developed CNS drugs have launched them

- Big Pharma wants the commercial launch de-risked before acquisition (e.g., Nurtec®)

Company		Mkt Cap <sup>1</sup>	Product	Indication	FDA Approval	Exit
Axsome	AXSM	\$3.5 B	Auvelity®	Depression	8/2022	
Biohaven	BHVN	\$3.0 B	Nurtec®	Migraine	2/2020	Sold to PFE for \$12 B in Oct 2022
IntraCellular	ITCI	\$7.2 B	Caplyta®	Schizophrenia	12/2019	
Supernus	SUPN	\$1.4 B	Oxtella-XR®	Seizures	1/2019	
Neurocrine	NBIX	\$13.6 B	Ingrezza®	Tardive Dyskinesia	4/2017	
Acadia	ACAD	\$2.5 B	Nuplazid®	Parkinson's psychosis	4/2016	

To prepare for the launch of TNX-102 SL, Tonix acquired two marketed Rx drugs: Zembrace® and Tosymra®

- Both are indicated for the acute treatment of migraine

<sup>1</sup>Accessed June 7, 2024



# Acute Stress Reaction (ASR) / Acute Stress Disorder (ASD)

*ASR/ASD are acute stress conditions resulting from trauma which can affect both civilian and military populations.*

## Large unmet need:

- According to National Center for PTSD, about 60% of men and 50% of women in the US are exposed least one traumatic experience in their lives<sup>1</sup>
- In the US alone, one-third of emergency department visits (40-50 million patients per year) are for evaluation after trauma exposures<sup>2</sup>

## Current standard of care:

- No medications are currently available at or near the point of care to treat patients suffering from acute traumatic events and support long-term health

<sup>1</sup>National Center for PTSD. How Common is PTSD in Adults? [https://www.ptsd.va.gov/understand/common/common\\_adults.asp](https://www.ptsd.va.gov/understand/common/common_adults.asp)

<sup>2</sup>Wisco et al. *J Clin Psychiatry*. 2014.75(12):1338-46





# TNX-102 SL for ASR/ASD: Program Status

**Status:** Expect to start investigator-initiated Phase 2 in 4Q 2024; received IND clearance from FDA

## Investigator-initiated Phase 2 Trial Funded by DoD grant to University of North Carolina (UNC)

- UNC Institute for Trauma Recovery awarded a \$3M grant from the Department of Defense (DoD)
- OASIS trial will build upon infrastructure developed through the UNC-led, \$40M AURORA initiative
  - AURORA study is a major national research initiative to improve the understanding, prevention, and recovery of individuals who have experienced a traumatic event
  - Supported in part by funding from the National Institutes of Health (NIH) and the health care arm of Google’s parent company Alphabet
- Opportunity to investigate the correlation between motor vehicle collisions and the emergence of ASD and PTSD
- Supported by multiple clinical trials:
  - Phase 2 trial in military-related PTSD (AtEase or NCT02277704)
  - Phase 3 trial in military-related PTSD (HONOR or NCT03062540)
  - Phase 3 trial in primarily civilian PTSD (RECOVERY or NCT03841773)
- In each of these studies, early and sustained improvements in sleep were associated with TNX-102 SL treatment by the PROMIS sleep disturbance (SD) scale and the Clinician Administered PTSD Scale (CAPS-5) “sleep disturbance” item.

***Together these studies provide preliminary evidence that TNX-102 SL is generally well-tolerated and may promote recovery from PTSD via a pharmacodynamic facilitation of sleep-dependent emotional memory processing***



# TNX-102 SL for ASR/ASD: Phase 2 OASIS Study Design

## General study characteristics:

- Randomized, double-blind, placebo-controlled study in Acute Stress Reaction (ASR) / Acute Stress Disorder (ASD)
- The proposed Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients presenting to the emergency department after a motor vehicle collision (MVC)
- The trial will enroll approximately 180 individuals who acutely experienced trauma at study sites across the US
- Participants will be randomized in the emergency department to receive a two-week course of either TNX-102 SL or placebo
- Investigator-initiated IND

## Objective:

- Investigate the potential of Tonix's TNX-102 SL (cyclobenzaprine HCl sublingual tablets) to reduce the frequency and severity of the adverse effects of traumatic exposure, including acute stress reaction (ASR), acute stress disorder (ASD), and posttraumatic stress disorder (PTSD).
- ASR refers to the body's immediate response to trauma, whereas ASD is the short-term effects of trauma (within 1 month), and PTSD is the long-term effects of trauma (beyond 1 month)

**TNX-102 SL once-daily at bedtime**  
5.6 mg (2 x 2.8 mg tablets)\*

**Placebo once-daily at bedtime**



\*First dose of TNX-102 SL 5.6 mg versus placebo taken in the emergency department, and then daily at bedtime to finish 2 weeks of treatment

## A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With ASR/ ASD (OASIS)

- Primary outcome measure: Acute Stress Disorder Scale (ASDS) assessed at 7 and 21 days post MVC
- Posttraumatic stress symptom severity assessed at 6 and 12 weeks post MVC using the PTSD Checklist for DSM-5 (PCL-5)
- Standardized survey instruments of sleep disturbances, anxiety and depression symptoms, general physical and mental health, and clinical global improvement also employed
- Detailed and brief neurocognitive assessments are performed from baseline to 12 weeks after MVC at specific timepoints throughout study participation period



## Significant Overlap between Fibromyalgia and Long-COVID

National Institutes of Health (NIH)-sponsored RECOVER study found many Long COVID patients suffer from pain at multiple sites<sup>1</sup>

- Suggests that many Long-COVID patients may meet the diagnostic criteria for fibromyalgia

Tonix has previously presented its analysis of real-world evidence from the TriNetX claims database suggesting that ***over 40% of Long COVID patients present with a constellation of symptoms that overlap with fibromyalgia***<sup>2,3</sup>

<sup>1</sup>Thaweethai T, et al. *JAMA*. 2023 329(22):1934-1946.

<sup>2</sup>Feb 22, 2023 Tonix Pharmaceuticals Press Release. URL: <https://ir.tonixpharma.com/news-events/press-releases/detail/1369/tonix-pharmaceuticals-describes-emerging-research-on-the>

<sup>3</sup>September 21, 2022, Tonix Pharmaceuticals Poster at the IASP, "Retrospective observational database study of patients with Long COVID with multi-site pain, fatigue and insomnia".

URL: [www.tonixpharma.com/wp-content/uploads/2022/09/Retrospective-Observational-Database-Study-of-Patients-with-Long-COVID-with-Multi-Site-Pain-Fatigue-and-Insomnia\\_A-Real-World-Analysis-of-Symptomatology-and-Opioid-Use.pdf](http://www.tonixpharma.com/wp-content/uploads/2022/09/Retrospective-Observational-Database-Study-of-Patients-with-Long-COVID-with-Multi-Site-Pain-Fatigue-and-Insomnia_A-Real-World-Analysis-of-Symptomatology-and-Opioid-Use.pdf)



## NASEM Definition of Long-COVID

- In June 2024, the US National Academies of Sciences, Engineering and Medicine (NASEM) described **fibromyalgia as a ‘diagnosable condition’ in people suffering from Long COVID<sup>1</sup>**
- This definition provides guidance to government, healthcare professionals and industry that fibromyalgia can arise after infection with the SARS-CoV-2 virus and can be diagnosed in Long COVID patients

***Fibromyalgia prevalence prior to COVID-19 pandemic: >10M adults in the US<sup>2</sup>***

***Long-COVID prevalence: 5.3% or ~14M adults in the US<sup>3</sup>***

**Tonix believes that diagnosing fibromyalgia in Long COVID patients will increase the potential market for TNX-102 SL as compared to market estimates from before the COVID-19 pandemic**

<sup>1</sup>U.S. National Academies of Sciences, Engineering, and Medicine. 2024. *A Long COVID Definition: A chronic, systemic disease state with profound consequences*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/27768>. <http://www.nationalacademies.org/long-covid-definition>.

<sup>2</sup>Vincent A, et al. *Arthritis Care Res (Hoboken)*. 2013 65(5):786-92. doi: 10.1002

<sup>3</sup>National Center for Health Statistics. U.S. Census Bureau, Household Pulse Survey, 2022–2024. Long COVID. Generated interactively: July 22, 2024 from <https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm>



# TNX-102 SL: Patents and Patent Applications

- **U.S. Composition:\***
  - A 75:25 cyclobenzaprine HCl - mannitol eutectic (dependent claims add a basifying agent).
    - 5 US Patents (Expire November 2034)
    - 1 Pending US Application (Would expire November 2034)
  - A composition of a cyclobenzaprine HCl and a basifying agent suitable for sublingual absorption.
    - 1 Pending US Application (Would expire June 2033)
- **U.S. Methods of Use\* (Specific Indications):**
  - Fibromyalgia
    - Pain, Sleep Disturbance, Fatigue
      - 1 Pending US Application (Would expire December 2041)
    - Early Onset Response
      - 1 Pending US Provisional Application (Would expire December 2044)
    - Depressive Symptoms
      - 1 Pending US Application (Would expire March 2032)
  - Sexual Dysfunction
    - 1 Pending US Application (Would expire October 2041)
  - PASC
    - 1 Pending US Application (Would expire June 2043)
  - PTSD
    - 1 US Patent (Expires November 2030)
  - Agitation (Dementia)
    - 1 US Patent (Expires December 2038)
    - 1 Pending US Application (Would expire December 2038)
  - Alcohol Use Disorder
    - 1 Pending US Application (Would expire November 2041)
- **Foreign Filings**
  - Corresponding foreign patents have been filed and some have issued:
    - Composition (25 patents, 3 allowed applications, 16 pending applications)
    - Methods of Use (9 patents, 54 pending applications)

\*US Patents: Issued: US Patent Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321. Pending: US Patent Application Nos. 13/918,692; 18/385,468; 13/412,571; 18/265,525; 63/612,352; 18/382,262; 18/037,815; 17/226,058; 18/212,500.

© 2024 Tonix Pharmaceuticals Holding Corp.



# TONIX MEDICINES: MARKETED PRODUCTS





## Tonix Medicines: Commercial-Stage Specialty Pharma Subsidiary

- **Tonix Medicines is a wholly-owned subsidiary of Tonix (NASDAQ: TNXP)**
  - Currently marketing two products indicated for the treatment of acute migraine: Zembrace<sup>®</sup> SymTouch<sup>®</sup> and Tosymra<sup>®</sup>
  - Nascent commercial organization
- **Tonix Medicines is preparing to launch TNX-102 SL for fibromyalgia**
  - Fibromyalgia care is relatively concentrated to specialized providers
  - We believe prescribing physicians can be targeted effectively by a specialty sales force
  - Evolving landscape in commercial markets favors distribution channels such as specialty pharmacies



# Two Marketed Proprietary Migraine Drugs Non-oral Formulations of Sumatriptan

## Zembrace® SymTouch® (sumatriptan injection) 3 mg<sup>1</sup>



- Each indicated for the **treatment of acute migraine with or without aura in adults**
- Sumatriptan remains the acute migraine ‘gold standard’ treatment for many patients and continues to represent the largest segment of the market in terms of unit sales<sup>3</sup>
- Each may provide migraine **pain relief in as few as 10 minutes** for some patients<sup>1,2,4,5</sup>
- Patents to 2036 (Zembrace) and 2031 (Tosymra)

## Tosymra® (sumatriptan nasal spray) 10 mg<sup>2</sup>



### Tonix Medicines Commercial Subsidiary

- Complete commercialization capability
  - Manage supply chain and contract manufacturer
  - Distribution
  - Trade, Managed Care & Government contracting
- Team of professionals including Sales & Marketing personnel

<sup>1</sup>Zembrace SymTouch [package insert]. For more information, talk to your provider and read the [Patient Information](#) and [Instructions for Use](#). – Important Safety Information is provided in the appendix

<sup>2</sup>Tosymra [package insert]. For more information, talk to your provider and read the [Patient Information](#) and [Instructions for use](#)– Important Safety Information is provided in the appendix

<sup>3</sup>Tonix Medicines, Inc.; Data On File, 2023

<sup>4</sup>Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.

<sup>5</sup>Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines, Inc. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly owned subsidiary of Neurelis, Inc.







# Zembrace and Tosymra Bypass the GI Tract

## Bypassing gastrointestinal (GI) tract is *potential advantage for treating acute migraine*

- GI absorption may be inconsistent in migraineurs due to gastric stasis (also called “gastroparesis”)<sup>1-4</sup>
- Nausea and vomiting are symptoms of migraine<sup>5</sup> which can complicate oral treatment

## Existing Subcutaneous injectable products

- Imitrex® SQ Injection (sumatriptan succinate)-6mg and 4mg preparations
- DHE 45 (dihydroergotamine mesylate) SQ Injection

## Existing intranasal products

- Imitrex® nasal spray (sumatriptan)
- Migranal® (dihydroergotamine) nasal spray – developed by Novartis, sold by Bausch Health
- Zavzpret® (zavegepant) nasal spray, FDA approved in March, 2023<sup>5</sup> is the first intranasal gepant-marketed by Pfizer
- Zomig® nasal spray (zolmitriptan)
- Onzetra® Xsail® (sumatriptan nasal powder) marketed by Currax
- Trudhesa® (dihydroergotamine) nasal spray

<sup>1</sup>Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: February 2021.

<sup>2</sup>Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.

<sup>3</sup>Landy, S. et al. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. *J Headache Pain*. 19, 69 (2018).

<sup>4</sup>Brand-Schieber E, Munjal S, Kumar R, et al. Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients. *Med Devices (Auckl)*. 2016;9:131-137.

<sup>5</sup>Pfizer Press Release March 10, 2023. – <https://www.pfizer.com/news/press-release/press-release-detail/pfizers-zavzprettm-zavegepant-migraine-nasal-spray>

# Pipeline

## Programs and Strategy for Partnerships

---

# Pipeline Development Strategy

---

## Focusing on government and academic collaborations

- Validates Tonix's scientific expertise and technology
- Reduces internal spend
- Increases number of trials
- Potentially speeds time to market
- Grants, contracts, cost-sharing or "in-kind" arrangements

# External Partnerships

Government partners providing direct funding, cost sharing or in-kind support include<sup>1</sup>:

- **National Institutes of Health (NIH)**
- **National Institute of Allergy and Infectious Disease (NIAID)**
  - TNX-1800 selected for Project NextGen
- National Institute on Drug Abuse (NIDA)
  - TNX-1300 for cocaine intoxication; Phase 2 study funding
- **Department of Defense (DoD)**
  - TNX-4200 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments
  - TNX-102 SL for ASD; investigator-initiated Phase 2 study funding

Academic partners sponsoring clinical trials of Tonix's investigational drug products include:

- Massachusetts General Hospital (MGH)
- University of Washington
- University of North Carolina

<sup>1</sup>Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

# Key Partnerships

## TNX-1500: ALLOGRAFT REJECTION



## TNX-102 SL: ACUTE STRESS DISORDER



U.S. Department of Defense



THE UNIVERSITY  
of NORTH CAROLINA  
at CHAPEL HILL

## TNX-2900: PRADER-WILLI SYNDROME



## TNX-1300: COCAINE INTOXICATION



National Institute  
on Drug Abuse



## TNX-1800: COVID-19 VACCINE



National Institutes  
of Health



National Institute of  
Allergy and  
Infectious Diseases

## TNX-4200: BROAD-SPECTRUM ANTIVIRAL



U.S. Department of Defense



# TNX-801

Live Virus Vaccine

---

*Live virus vaccine platform with multitude of potential applications*

# Mpox Declared Public Health Emergency of International Concern (PHEIC) by WHO\* on August 14, 2024: New Clade I = “Clade Ib”



- **Clade Ib - first wave in Democratic Republic of Congo (DRC)**
  - Affects children
  - New mutations
  - ~0.5% mortality
  - Affects both MSM (men who have sex with men) + heterosexual transmission primarily in adults
  - 2024 mpox epidemic has spread to 16 countries in Africa
  - Outside of Africa cases identified in Sweden, Thailand, Singapore, India, Germany and England
- **Two FDA\*\*-approved vaccines:**
  - Jynneos® (Bavarian-Nordic) – requires 2 dose regimen
    - Durability of neutralization antibody titers being studied<sup>1,2</sup>
    - Also approved for use in adults by the WHO<sup>3</sup>
  - ACAM 2000 (Emergent) – single-dose, reactogenic
    - Provides durable protection
    - Approved for people at high risk of mpox infection<sup>4</sup>

\*WHO = World Health Organization

<sup>1</sup>Zaack LM, *Nat Med*. 2023 29(1):270-278. doi: 10.1038/s41591-022-02090

<sup>2</sup>Berens-Riha N, et al. *Euro Surveill*. 2022 27(48):2200894. doi: 10.2807/1560-7917.ES.2022.27.48.2200894.

<sup>3</sup>Keaton, J. Sept. 13, 2024. *Associated Press*. “WHO grants first mpox vaccine approval to ramp up response to disease in Africa.” URL: <https://bit.ly/4e4yyeb>

<sup>4</sup><https://www.fda.gov/vaccines-blood-biologics/vaccines/key-facts-about-vaccines-prevent-mpox-disease#:~:text=ACAM2000%20Vaccine,for%20smallpox%20or%20mpox%20infection.>





# Mpox Outbreak 2022-23: Clade IIb

## Public Health Emergency Global Health Concern

### Risk of Spread and Lethality of Clade IIb

- Case Fatality Rate (CFR): 0.1% to 3.6% → Lower compared to Clade I
- Primarily spread through sexual contact among MSM (men who have sex with men)
- Rapid and significant spread beyond endemic regions → Over 90,000 cases reported in more than 100 countries by the end of 2022
- Systemic symptoms and rash leading to medical interventions in up to 40% of cases



Total Cases: 95,912; 92,982 were in locations that have not historically reported Mpox  
 Total Location: 118; 111 has not historically reported Mpox

Sources: WHO, European CDC, US CDC, and Ministries of Health  
[2022 U.S. Map and Case Count | Mpox | Poxvirus | CDC](#)  
 WHO = World Health Organization  
 FDA = U.S. Food and Drug Administration






# Monkeypox Headlines

- Multiple recent statements by U.S. Agencies warning about smallpox and monkeypox<sup>1-6</sup>
- U.S. National Academy of Sciences Consensus Report (March, 2024)<sup>6</sup>
  - *“Additionally, safer, single-dose vaccines and a diverse set of therapeutic options against smallpox would improve the U.S. readiness and response posture for immediate containment and long-term protection in a smallpox emergency.*
  - *“Smallpox vaccines that have improved safety across different population subgroups and are available as a single dose would support faster and more effective response to contain smallpox and other orthopoxvirus outbreaks. The development of novel smallpox vaccines using multi-vaccine platforms (i.e., use common vaccine vectors, manufacturing ingredients, and processes) would improve the capacity for rapid vaccine production in response to a smallpox event and reduce the need for stockpiling in the SNS at current levels.*
  - *“Given the lack of commercially available orthopoxvirus diagnostics, vaccines, and therapeutics, planning for logistics and supply chain management considerations is critical. Efforts could give consideration to developing plans to increase the number of smallpox vaccine and therapeutics manufacturers as well as optimizing current manufacturing capacities should they be needed in the shorter term.”*

<sup>1</sup> Office of Science and Technology Policy (OSTP). American Pandemic Preparedness: Transforming Our Capabilities. September 2021  
<sup>2</sup> National Biodefense Science Board (NBSB). Prioritization of Product Attribute Categories to Maximize Access for Next Generation COVID-19 Vaccines and Therapeutics. August 2023  
<sup>3</sup> Office of Science and Technology Policy (OSTP). American Pandemic Preparedness: Transforming Our Capabilities. September 2021  
<sup>4</sup> National Biodefense Science Board (NBSB). Prioritization of Product Attribute Categories to Maximize Access for Next Generation COVID-19 Vaccines and Therapeutics. August 2023  
<sup>5</sup> BARDA Strategic Plan 2022-2026.  
<sup>6</sup> U.S. National Academy of Sciences. March 28, 2024. “Consensus Study Report: Future State of Smallpox Medical Countermeasures.” <https://nap.nationalacademies.org/catalog/27652/future-state-of-smallpox-medical-countermeasures>

# TNX-801: Recombinant Pox Vaccine (RPV) Platform Using Live Virus Technology

Cloned version of horsepox<sup>1</sup> purified from cell culture



## Key Differentiators

### Live virus vaccines are the most established vaccine technology

- Prevents forward transmission
- Effective in eliciting durable or long-term immunity

### Economical to manufacture at scale

- Low dose because replication amplifies dose *in vivo*
- Single administration

### Standard refrigeration for shipping and storage



## TNX-801: Pre-IND Ready Candidate Mpox Vaccine

- Based on synthetic horsepox-vector, believed related to first smallpox vaccine used by Dr. Edward Jenner in 1796
- Single-dose percutaneous
- Attenuated live virus for durable T-cell immunity similar to 19<sup>th</sup> Century vaccinia
- Believed to be thermo stable in ultimate lyophilized formulation
- Eventual presentation using Micro Array Patch – working with developers




R&D Center- Maryland  
Operational BSL-3 capable



Advanced Manufacturing Center- MA  
GMP-manufacturing capability\*

\*GMP Suites currently decommissioned


# Illustrative Safety Spectrum Of Pox-based Vaccine Vectors Optimizing Live Virus Vaccines



# Immunogenicity and Efficacy in NHPs – Study Design

Vaccination					Challenge		
Group	Vaccine	N	Dose (Log <sub>10</sub> PFU)	Route	Virus	Dose (Log <sub>10</sub> PFU)	Route
1	TNX-801 (High)	4	6.6	Percutaneous	<i>MPXV (Zaire) Clade Ia</i>	5.0	<i>IT</i>
2	TNX-801 (Low)	4	5.7	Percutaneous			
3	rVACV*	4	5.0	Percutaneous			
4	Mock	4	-	Percutaneous			

\*rVACV = Synthetic vaccinia virus (VACV) similar to ACAM2000 (FDA Approved smallpox and mpox vaccine)




**“Take” observed in all TNX-801 vaccinated NHPs except one.**

- If no take by day 7 NHPs were revaccinated on day 14.

**Post-vaccination, no NHP showed lesions during first 60 days**


# Immunogenicity: Total IgG (ELISA)



**100% Seroconversion in  
TNX-801 vaccinated groups**



HD = "High Dose"  
LD = "Low Dose"

# Immunogenicity: Neutralizing Antibody (PRNT<sub>50</sub> Assay)



**100% Seroconversion and 88% of TNX-801 vaccinated NHPs had neutralizing antibody responses 8- to 50-fold from baseline**

# Clinical Signs (Lesions) After MPXV Challenge




**No lesions observed after MPXV challenge in any of the vaccinated animals**

<sup>1</sup>Noyce RS, et al. *Viruses*. 2023 Jan 26;15(2):356. doi: 10.3390/v15020356. PMID: 36851570; PMCID: PMC9965234.



## Clinical Disease: Lethality



**100% survival in TNX-801 vaccinated animals**



## TNX-1800\*: Designed to Express the SARs-CoV-2 Spike Protein

TNX-1800 (recombinant horsepox virus) is a live virus vaccine based on Tonix's TNX-801 that is designed to express the spike protein of the SARS-CoV-2 virus and to elicit a predominant T cell response

- Immunogenic and well tolerated<sup>1</sup>
- Showed promise in protecting animals from challenge with SARS-CoV-2 delivered directly into the lungs<sup>1</sup>

**Status: National Institute of Allergy and Infectious Diseases (NIAID) will conduct a Phase 1 clinical trial with TNX-1800**

- First vaccine candidate using Tonix's live virus recombinant pox virus (RPV) platform technology to enter clinical trials
- "Project NextGen" is an initiative by the U.S. Department of Health and Human Services (HHS) to advance a pipeline of new, innovative vaccines and therapeutics for COVID-19. NIAID will be conducting clinical trials to evaluate several early-stage vaccine candidates, including TNX-1800
- Phase 1 study is designed to assess safety and immunogenicity in approximately 60 healthy adult volunteers
- Upon completion of the trial, NIAID and Tonix will assess the results and determine the next steps for the development of TNX-1800

\*TNX-1800 is in the pre-IND stage of development and has not been approved for any indication

<sup>1</sup>Awasthi, M. et al. *Viruses*. 2023. 15(10):2131.

<sup>2</sup>Awasthi, M. et al. *Vaccines (Basel)*. 2023. 11(11):1682.



**TONIX**  
PHARMACEUTICALS

# INFECTIOUS DISEASE: KEY CANDIDATES



# Broad-Spectrum Antiviral Discovery Programs

## Host-directed antiviral discovery programs

- **TNX-4200\*: CD45 targeted therapeutics**
  - Small molecule therapeutics that reduce endogenous levels of CD45, a protein tyrosine phosphatase
  - Reduction in CD45 protects against many viruses including the Ebola virus
- **Cathepsin inhibitors**
  - Small molecule therapeutics that inhibit **essential cathepsins** which are required by viruses such as coronaviruses and filoviruses to infect cells
  - Activity as monotherapy and in combination with other antivirals

## Virus-directed antivirals discovery program

- **Viral glycan-targeted engineered biologics**
  - Bind to viral densely branched high-mannose (DBH) glycans
  - **Neutralize circulating virus** and stop the entry of the progeny virus into cells
  - Antiviral activity against a broad range of RNA viruses
  - Activity as monotherapy and in combination with other antivirals

## R&D Center (RDC): Frederick, MD

- Accelerated development of vaccines and antiviral drugs against infectious diseases
- ~48,000 square feet, BSL-2 with some areas designated BSL-3

\*TNX-4200 is in the pre-IND stage of development and has not been approved for any indication



## Tonix Awarded Contract from DoD



U.S. Department of Defense

***Defense Threat Reduction Agency (DTRA) contract is expected to advance development of Tonix's broad-spectrum oral antiviral program, TNX-4200, for medical countermeasures***

- Other Transaction Agreement (OTA) with a potential for up to \$34 million over five years
- Objective is to develop small molecule, broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments
- Tonix's focus is to develop an orally available CD45 antagonist with broad-spectrum efficacy against a range of viral families through preclinical evaluation
  - Program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an IND submission and to fund a first-in-human Phase 1 clinical study

# TNX-2900


Intranasal Potentiated Oxytocin with Magnesium

---

*A novel, non-CGRP antagonist approach to treatment*

# TNX-2900: Novel Formulation of Intranasal Oxytocin (OT) Potentiated with Magnesium

*Magnesium is known to potentiate the binding of OT to its receptor<sup>1,2</sup>*



## Key Differentiators

- Targeted intranasal delivery
  - Low systemic exposure
- When delivered via the nasal route, concentrates in trigeminal system
  - Binding of OT to receptors on neurons in trigeminal system inhibits release of CGRP and transmission of pain signals
  - Blocking CGRP release is a distinct mechanism compared with CGRP antagonist and anti-CGRP antibody drugs, which block the binding of CGRP to its receptor

<sup>1</sup>Antoni et al., 1989. *Biochem J.* 257(2):611-4

<sup>2</sup>Meyerowitz et al., 2022. *Nat Struct Mol Biol.* (3):274-281

\*TNX-2900 has not been approved for any indication.



# About Prader-Willi Syndrome

*Prader-Willi Syndrome (PWS) is the most common genetic cause of life-threatening childhood obesity. PWS causes unhealthy behaviors around food<sup>1-4</sup>, consequences such as **obesity, type 2 diabetes, and cardiovascular disease**<sup>1-5</sup>, and creates significant caretaker burden<sup>1-4</sup>*

**10-20** Rare genetic disease that afflicts 10-20 thousand individuals in the US  
*thousand individuals*

### Current standard of care:

- Human growth hormone treatment is FDA-approved for growth failure in PWS children

### Large unmet need:

- Currently no cure, and no treatment for PWS-related hyperphagia
- Consequences can be life threatening - obesity and cardiovascular disease are leading cause of death

***\*TNX-2900 has been granted FDA Orphan Drug and Rare Pediatric Disease Designations, and received IND clearance by FDA for Phase 2 Trial***

<sup>1</sup>Miller et al., 2011. *Am J Med Genet A*. 155A(5):1040-1049

<sup>2</sup>Butler et al., 2017. *Genet Med*. 19(6):635-642

<sup>3</sup>Butler MG. NORD. Updated 2018. Accessed May 25, 2022. <https://rarediseases.org/rare-diseases/prader-willi-syndrome/>

<sup>4</sup>Prader-Willi Syndrome Association USA. Accessed May 25, 2022. <https://www.pwsausa.org/what-is-prader-willi-syndrome/>

<sup>5</sup>Muscogiuri et al., 2021. *J Endocrinol Invest*. 44(10):2057-2070





# TNX-1300

## Cocaine Esterase

---

*Fast acting antidote for life threatening cocaine intoxication*

# TNX-1300: Recombinant Protein Rapidly Degrades Cocaine in the Bloodstream

*Drops plasma exposure by 90% in 2 minutes*



## ***Key Differentiators***

- Rapidly metabolizes cocaine within matter of minutes
- No other product currently on the market for this indication



# About Cocaine Intoxication

*Over 5 million Americans reported current cocaine use in 2020, which is almost 2% of the population<sup>1</sup>. In 2021, more than 24,900 individuals in the US died from drug overdose deaths involving cocaine<sup>2</sup>*

**500k** Over 500,000 emergency department visits for cocaine, annually<sup>3,4</sup>

## Current standard of care:

- Patients are currently managed only by supportive care for the adverse effects of cocaine intoxication on the cardiovascular and central nervous systems

## Large unmet need:

- No other product currently on the market for this indication
- TNX-1300 could significantly reduce the time and resources required for other detox services
- Potentially reduces the risk of morbidity and mortality

<sup>1</sup>Substance Abuse and Mental Health Services Administration. (2021). Results from the 2020 National Survey on Drug Use and Health: Detailed Tables: Prevalence Estimates, Standard Errors, and Sample Sizes.

<sup>2</sup>Centers for Disease Control and Prevention (CDC) - <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>


<sup>3</sup>Substance Mental Health Services Administration, Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.

<sup>4</sup> Drug Abuse Warning Network, 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Center for Behavioral Health Statistics and Quality, SAMHSA, 2013.



**TONIX**  
PHARMACEUTICALS

**IMMUNOLOGY: KEY  
CANDIDATES**



# TNX-1500

Anti-CD40L Monoclonal Antibody

---

*Next Generation mAb preserves efficacy without risk of thrombosis*

# TNX-1500: Next Generation anti-CD40L mAb

Re-engineered to better modulate the binding of FcγR and mitigate risk of thrombosis

Clinical Stage of Phase 1 study completed


## Key Differentiators

Expected to deliver efficacy without compromising safety

**First Generation:** Development halted due to thromboembolic (TE) complications—blood clots—traced to Fc gamma receptor (FcγR)

**Second Generation:** Eliminated the FcγR TE complication but potency and half life was reduced, limiting utility

**Third Generation (TNX-1500):** Re-engineered to better modulate the binding of FcγR.



Contains the full ruplizumab Fab and the engineered Fc region that modulates FcγR-binding, while preserving FcRn function



# TNX-1500 Strategy and Status

- 1 Proposed Initial Indication: Prevention of Allograft Rejection**  
*Status: Clinical stage Phase 1 complete*  
Collaborations ongoing with Mass General Hospital on heart and kidney transplantation in non-human primates
  - Collaboration with Boston Children’s on bone marrow transplantation in non-human primates**Next Steps:** Initiate Phase 2 study in Kidney Transplant Recipients
- 2 Second Indication: Hematopoietic Cell Transplant (Bone Marrow Transplant)**
  - Potential to reduce GvHD
- 3 Third Indication (and beyond): Autoimmune Diseases (e.g., Multiple Sclerosis, Sjögren’s Syndrome, Systemic Lupus Erythematosus)**
  - These indications require large studies, but represent large target markets

*Currently exploring strategic partnerships and out-licensing opportunities*



# TNX-1500 Preclinical Data and Publications

## Non-human Primate Kidney Allo-Transplantation

- TNX-1500 monotherapy consistently prevents kidney transplant rejection with no thrombosis observed
- April 2023 Publication: Lassiter, G., et al. (2023). TNX-1500, an Fc-modified Anti-CD154 Antibody, Prolongs Nonhuman Primate Renal Allograft Survival. *American Journal of Transplantation*. [www.sciencedirect.com/science/article/pii/S1600613523003714](http://www.sciencedirect.com/science/article/pii/S1600613523003714)

## Non-human Primate Heart Heterotopic Allo-Transplantation

- TNX-1500 monotherapy consistently prevents heart transplant rejection. Similar activity to chimeric hu5c8<sup>2</sup> during treatment phase in prior studies
- April 2023 Publication: Miura, S., et al. (2023) TNX-1500, an Fc-modified Anti-CD154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival. *American Journal of Transplantation*. [www.sciencedirect.com/science/article/pii/S1600613523003969](http://www.sciencedirect.com/science/article/pii/S1600613523003969)

## Non-Human Primate Kidney Xenograft Transplantation

- TNX-1500 therapy is part of a regiment to prevent rejection in kidney xenograft transplants
  - Anand, R.P., Layer, J.V., Heja, D. et al. (2023). Design and testing of a humanized porcine donor for xenotransplantation. *Nature*. <https://www.nature.com/articles/s41586-023-06594-4>
  - Kozlov, M. (2023). Monkey survives two years after gene-edited pig-kidney transplant. *Nature*. <https://www.nature.com/articles/d41586-023-03176-2>
  - Mohiuddin, M. (2023). Pig-to-primate organ transplants require genetic modifications of donor. *Nature*. <https://www.nature.com/articles/d41586-023-02817-w>





# α-CD40L Headlines

- Mass General Hospital just transplanted a genetically engineered pig kidney into a living human<sup>1</sup>
  - Boston Globe, March 21, 2024
  - Patient’s death announced May 11, 2024<sup>2</sup>
- The patient was being treated with anti-CD40L mAb tegoprubart from Eledon<sup>1</sup>
- **The preclinical work was performed with TNX-1500<sup>3</sup>**

<sup>1</sup> Massachusetts General Hospital press release. March 21, 2024. “World’s First Genetically Edited Pig Kidney Transplant into Living Recipient Performed at Massachusetts General Hospital.”

[www.massgeneral.org/news/press-release/worlds-first-genetically-edited-pig-kidney-transplant-into-living-recipient](http://www.massgeneral.org/news/press-release/worlds-first-genetically-edited-pig-kidney-transplant-into-living-recipient) (accessed March 29, 2024)

<sup>2</sup> Stoico, N. *Boston Globe*. May 11, 2023. “Mass Man who received first kidney transplant from genetically engineered pig has died, family says”.

<sup>3</sup> Anand, R.P., et al *Nature*. 622, 393–401 (2023). <https://doi.org/10.1038/s41586-023-06594-4>

## The Boston Globe

### In a first, Mass. General surgeons transplant a pig kidney into a man

The patient is doing well, but many unknowns remain

By Felice J. Freyer Globe Staff, Updated March 21, 2024, 7:40 p.m.




Dr. Leonardo V. Riella, medical director of kidney transplantation, center, broke down as he thanked his colleagues. Dr. Tatsuo Kawai, director of the Legorreta Center for Clinical Transplant Tolerance, left, and Dr. Winfred Williams, associate chief of the Division of Nephrology, also spoke at a news conference on Thursday. DAVID L. RYAN/GLOBE STAFF

Seventy years after surgeons at Brigham & Women’s Hospital performed the world’s first kidney transplant, doctors at its sister hospital, Massachusetts General, announced an



# Anti-CD40L Headlines

- Sanofi recently published their Phase 2 data on their frexalimab in multiple sclerosis in the *New England Journal of Medicine*<sup>1</sup>
  - Sanofi projects its Fc-modified humanized anti-CD40L mAb frexalimab will exceed €5 B per year in peak sales<sup>2</sup>
- Like frexalimab, TNX-1500 is Fc-modified to reduce/eliminate the risk of thrombosis seen with “first generation” anti-CD40L mAbs.



<sup>1</sup> Vermersch P, et al. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. PMID: 38354138.

<sup>2</sup> Dunn, A. Endpoints. December 7, 2023. "Sanofi CEO Paul Hudson pitches 12 blockbusters in a bid to convince investors on boosting R&D spend". <https://endpts.com/sanofi-rd-day-ceo-paul-hudson-touts-12-blockbusters-ups-rdspend/>

# TNX-1700


Recombinant Trefoil Factor Family Member 2 (rTFF2-HSA)  
Fusion Protein

---

*Targeting the toxic tumor micro-environment*

# TNX-1700: Fighting Cancer by Targeting the Tumor Micro-Environment

*Suppresses myeloid-derived suppressor cells (MDSCs) and activates anti-cancer CD8+ T cells*



## Key Differentiators

- Different MOA than checkpoint inhibitors
- **Potential synergy with anti-PD-1 or anti-PD-L1 monoclonal antibodies**

## Preclinical Evidence

- mTNX-1700 (mTFF2-MSA fusion protein) and anti-PD-1 monotherapy each was able to evoke anti-tumor immunity in the MC38 model of colorectal cancer<sup>1</sup>
- mTNX-1700 augmented the anti-tumor efficacy of anti-PD-1 therapy in both the MC38 and the CT26.wt models<sup>1</sup>

\*TNX-1700 is in the pre-IND stage of development and has not been approved for any indication.

<sup>1</sup>Daugherty, B. et al. March 6, 2023 Keystone Poster, <https://bit.ly/48nIRHM>



# About Gastric and Colorectal Cancer

*Gastric and colorectal cancer are both leading cancers in the US. Colorectal cancer is the 3<sup>rd</sup> leading cause of cancer-related deaths in both men and women.<sup>1</sup>*

**>1.3M** People living with colorectal cancer in the US<sup>2</sup>

**>125k** People living with gastric cancer in the US<sup>3</sup>

**Current standard of care:**

- PD-1 blockade
  - However, gastric and colorectal cancer are relatively unresponsive

**Large unmet need:**

- Gastric and colorectal cancer have a relative 5-year survival rate of 35.7% and 65%, respectively
  - Despite advances in the field, patients are still in need of life saving treatment

<sup>1</sup>American Cancer Society, accessed September 2023 - <https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html>

<sup>2</sup>NIH, accessed September 2023 - <https://seer.cancer.gov/statfacts/html/colorect.html>

<sup>3</sup>NIH, accessed September 2023 - <https://seer.cancer.gov/statfacts/html/stomach.html>



**TONIX**  
PHARMACEUTICALS

**TEAM,  
NETWORK, &  
UPCOMING  
MILESTONES**



# Management Team



**Seth Lederman, MD**  
Co-Founder, CEO & Chairman



**Gregory Sullivan, MD**  
Chief Medical Officer



**Bradley Saenger, CPA**  
Chief Financial Officer



**Jessica Morris**  
Chief Operating Officer



# Milestones: Recently Completed and Upcoming

## TNX-102 SL for the Management of Fibromyalgia Milestones

- 4<sup>th</sup> Quarter 2023 Statistically significant topline results of Phase 3 RESILIENT study – 2<sup>nd</sup> statistically significant Phase 2 trial
- 2<sup>nd</sup> Quarter 2024 Type B CMC and clinical pre-NDA meetings with FDA
- 3<sup>rd</sup> Quarter 2024 FDA Fast Track Designation granted by FDA
- October 2024 Submitted NDA to FDA for TNX-102 SL for fibromyalgia in October 2024
- December 2024 FDA decision expected on NDA acceptance for review
- 2025 FDA decision expected on NDA approval (“PDUFA\*” Date)

## Other Key Program Milestones

- 3<sup>rd</sup> Quarter 2024 U.S. DoD / DTRA Awarded up to \$34 M contract (over 5 years) for broad spectrum antiviral development (TNX-4200)
- 3<sup>rd</sup> Quarter 2024 Initiate Phase 2 study of TNX-1300 for the treatment of cocaine intoxication
- 4<sup>th</sup> Quarter 2024 Initiate Phase 2 study of TNX-102 SL for acute stress disorder

\*PDUFA = Prescription Drug User Fee Act



THANK YOU





## Zembrace® Important Safety Information (1 of 2)

**Zembrace SymTouch (Zembrace) can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:**

- Discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back; severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw; pain or discomfort in your arms, back, neck, jaw or stomach; shortness of breath with or without chest discomfort; breaking out in a cold sweat; nausea or vomiting; feeling lightheaded

Zembrace is not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.

Do not use Zembrace if you have:

- History of heart problems; narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease); uncontrolled high blood pressure; hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
- Had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation; severe liver problems; taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, dihydroergotamine; are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
- An allergy to sumatriptan or any of the components of Zembrace

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.

Zembrace can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.



## Zembrace® Important Safety Information (2 of 2)

### Zembrace may cause serious side effects including:

- Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet; increased blood pressure including a sudden severe increase even if you have no history of high blood pressure; medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
- Serotonin syndrome, a rare but serious problem that can happen in people using Zembrace, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
- Hives (itchy bumps); swelling of your tongue, mouth, or throat
- Seizures even in people who have never had seizures before

The most common side effects of Zembrace include: pain and redness at injection site; tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired.

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace. For more information, ask your provider.

This is the most important information to know about Zembrace but is not comprehensive. For more information, talk to your provider and read the [Patient Information](#) and [Instructions for Use](#). For full Prescribing Information, visit:

<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e5b104f-2b9e-416e-92fb-ef1bdaea867d>

You are encouraged to report adverse effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Zembrace is a prescription medicine used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.

Zembrace is not used to prevent migraines. It is not known if it is safe and effective in children under 18 years of age.



## Tosymra® Important Safety Information (1 of 2)

**Tosymra® can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop Tosymra and get emergency medical help if you have any signs of heart attack:**

- Discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back; severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw; pain or discomfort in your arms, back, neck, jaw, or stomach; shortness of breath with or without chest discomfort; breaking out in a cold sweat; nausea or vomiting; feeling lightheaded

Tosymra is not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam is done and shows no problem.

Do not use Tosymra if you have:

- History of heart problems; narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease); uncontrolled high blood pressure; severe liver problems; hemiplegic or basilar migraines. If you are not sure if you have these, ask your healthcare provider.
- Had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation; taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider if you are not sure if your medicine is listed above
- are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure
- An allergy to sumatriptan or any ingredient in Tosymra

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.



## Tosymra® Important Safety Information (2 of 2)

### Tosymra may cause serious side effects including:

- Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cramping and pain in your legs or hips, feeling of heaviness or tightness in your leg muscles, burning or aching pain in your feet or toes while resting, numbness, tingling, or weakness in your legs, cold feeling or color changes in one or both legs or feet; increased blood pressure including a sudden severe increase even if you have no history of high blood pressure; medication overuse headaches from using migraine medicine for 10 or more days each month. **If your headaches get worse, call your provider.**
- Serotonin syndrome, a rare but serious problem that can happen in people using Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. **Call your provider right away if you have:** mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
- Seizures even in people who have never had seizures before

### The most common side effects of Tosymra include:

tingling, dizziness, feeling warm or hot, burning feeling, feeling of heaviness, feeling of pressure, flushing, feeling of tightness, numbness, application site (nasal) reactions, abnormal taste, and throat irritation.

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Tosymra. For more information, ask your provider.

This is the most important information to know about Tosymra but is not comprehensive. For more information, talk to your provider and read the [Patient Information and Instructions for use](#). For full Prescribing Information, visit:

<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=015a5cf9-f246-48bc-b91e-cd730a53d8aa>.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Tosymra is a prescription medicine used to treat acute migraine headaches with or without aura in adults.

Tosymra is not used to treat other types of headaches such as hemiplegic or basilar migraines or cluster headaches.

Tosymra is not used to prevent migraines. It is not known if Tosymra is safe and effective in children under 18 years of age.